MedTrace Logo

Acute Montelukast in Asthma

NCT01011452 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2009-11-11

No results posted yet for this study

Summary

Patients presenting to hospital with an acute asthma exacerbation severe enough to require admission would receive full standard treatment according to British Thoracic Society guidelines in addition they would be offered the opportunity to take part in the study which would requite them to take a capsule of either montelukast or placebo.

Conditions

  • Acute Asthma Exacerbation

Interventions

DRUG

Montelukast

1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks

DRUG

Placebo

1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks

Sponsors & Collaborators

  • Norfolk Association of Asthma Nurses

    collaborator UNKNOWN

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • University of East Anglia

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2004-08-31
Completion
2004-10-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01011452 on ClinicalTrials.gov